Risk of endometrial cancer down with intentional weight loss

February 7, 2017

(HealthDay)—Losing weight is associated with a significantly lower risk of endometrial cancer, and that benefit appears to be greatest in obese women, according to a study published online Feb. 6 in the Journal of Clinical Oncology.

The researchers reviewed data from 36,794 American women between the ages of 50 and 79. The study included an average of more than 10 years of follow-up.

Women over 50 who lost 5 percent or more of their had a 29 percent lower risk of endometrial cancer, regardless of their age or how much weight they lost, according to the researchers. Obese women who lost 5 percent or more of their body weight had a 56 percent reduction in their risk. Overweight or who achieved a normal body mass index (BMI) had the same risk as women who maintained a normal BMI. The researchers also found that women who gained more than 10 pounds had a 26 percent increased risk of .

"Many think it's too late to benefit from weight loss, or think that because they are overweight or obese, the damage has already been done. But our findings show that's not true," study author Juhua Luo, Ph.D., an associate professor of epidemiology and biostatistics at the Indiana University Bloomington School of Public Health, said a news release from the American Society of Clinical Oncology. "It's never too late, and even moderate weight loss can make a big difference when it comes to cancer risk."

Explore further: Significant weight gain in adulthood increased risk for endometrial cancer

More information: Full Text
Editorial

Related Stories

Inadequate weight gain in overweight moms tied to SGA

August 5, 2014

(HealthDay)—For overweight and obese women, inadequate weight gain is associated with increased risk of small for gestational age (SGA), according to a study published in the August issue of the America Journal of Obstetrics ...

Recommended for you

Targeted drug shows promise in rare advanced kidney cancer

June 23, 2017

Some patients with a form of advanced kidney cancer that carries a poor prognosis benefited from an experimental drug targeted to an abnormal genetic pathway causing cancerous growth, according to research led by a Dana-Farber ...

0 comments

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.